Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Susanne Isfort & Tim H Brümmendorf. (2018) Bosutinib in chronic myeloid leukemia: patient selection and perspectives. Journal of Blood Medicine 9, pages 43-50.
Read now
Read now
Massimo Breccia & Fabio Efficace. (2016) Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?. Current Medical Research and Opinion 32:8, pages 1453-1454.
Read now
Read now
Articles from other publishers (18)
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Valentin Garcia-Gutiérrez, Michael W. Deininger & Jorge E. Cortes. (2022) Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Reviews 56, pages 100968.
Crossref
Crossref
Kelly L Schoenbeck, Ehab Atallah, Li Lin, Kevin P Weinfurt, Jorge Cortes, Michael W N Deininger, Vamsi Kota, Richard A Larson, Michael J Mauro, Vivian G Oehler, Javier Pinilla-Ibarz, Jerald P Radich, Charles A Schiffer, Neil P Shah, Richard T Silver, James E Thompson & Kathryn E Flynn. (2022) Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. JNCI: Journal of the National Cancer Institute 114:1, pages 160-164.
Crossref
Crossref
Kelly L. Schoenbeck & Kathryn E. Flynn. (2021) Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions. Current Hematologic Malignancy Reports 16:6, pages 491-499.
Crossref
Crossref
Foulon S, Cony-Makhoul P, Guerci-Bresler A, Daban M, Kapso R, Tubert-Bitter P & Bonastre J. (2021) Health state utility and quality of life measures in patients with chronic myeloid leukemia in France. Quality of Life Research 30:7, pages 2021-2032.
Crossref
Crossref
Andreas Hochhaus, Carlo Gambacorti-Passerini, Camille Abboud, Bjørn Tore Gjertsen, Tim H. Brümmendorf, B. Douglas Smith, Thomas Ernst, Pilar Giraldo-Castellano, Ulla Olsson-Strömberg, Susanne Saussele, Nathalie Bardy-Bouxin, Andrea Viqueira, Eric Leip, T. Alexander Russell-Smith, Jocelyn Leone, Gianantonio Rosti, Justin Watts, Francis J. Giles, E. Abruzzese, L. P. Akard, A. Bosi, F. Cervantes, A. Charbonnier, F. Di Raimondo, G. Etienne, V. Garcia Gutierrez, A. P. Guerci-Bresler, H Hjorth-Hansen, J. M. Karsenti, K. R. Kelly, P. Le Coutre, C. Martinez Chamorro, V. G. Oehler, G. Orti Pascual, A. Petzer, E. Pungolino, G. Rege-Cambrin, F. Rigal-Huguet, G. J. Roboz, P. Rousselot, F. M. Sanchez-Guijo, G. Sanz Santillana, P. Schafhausen, C. Scheid, S. Schmidt, G. Specchia, J. L. Steegmann & L. Stenke. (2020) Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia 34:8, pages 2125-2137.
Crossref
Crossref
Dominik Golicki, Katarzyna Jaśkowiak, Alicja Wójcik, Katarzyna Młyńczak, Iwona Dobrowolska, Andżelika Gawrońska, Grzegorz Basak, Emilian Snarski, Malwina Hołownia-Voloskova, Michał Jakubczyk & Maciej Niewada. (2020) EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review. Value in Health 23:7, pages 953-968.
Crossref
Crossref
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg & Anthony Mato. (2020)
Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect
®
CLL Registry
. eJHaem 1:1, pages 188-198.
Crossref
Crossref
Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Andrew G. Bushmakin, Joseph C. Cappelleri, Andrea Viqueira, Arlene Reisman, Susanne Isfort & Carla Mamolo. (2020) Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. Annals of Hematology 99:6, pages 1241-1249.
Crossref
Crossref
Andrea Petermann-Meyer & Susanne Isfort. (2020) Psychoonkologische Aspekte in der CML-Behandlung. InFo Hämatologie + Onkologie 23:5, pages 14-17.
Crossref
Crossref
Abdulkadir Ercaliskan & Ahmet Emre Eskazan. (2020) Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia. Future Oncology 16:3, pages 4425-4428.
Crossref
Crossref
Carlo Gambacorti-Passerini, Philipp le Coutre & Rocco Piazza. (2020) The role of bosutinib in the treatment of chronic myeloid leukemia. Future Oncology 16:2, pages 4395-4408.
Crossref
Crossref
Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Dragana Milojkovic, Philipp le Coutre, Valentin Garcia-Gutierrez, Rocco Crescenzo, Carla Mamolo, Arlene Reisman, Andreas Hochhaus & Tim H. Brümmendorf. (2019) Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 145:6, pages 1589-1599.
Crossref
Crossref
Lu Yu, Haibo Wang, Darko Milijkovic, Xiaojun Huang & Qian Jiang. (2018) Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer 18:1.
Crossref
Crossref
Hagop M. Kantarjian, Carla M. Mamolo, Carlo Gambacorti-Passerini, Jorge E. Cortes, Tim H. Brümmendorf, Yun Su, Arlene L. Reisman, Mark Shapiro & Jeff H. Lipton. (2018) Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer 124:3, pages 587-595.
Crossref
Crossref
Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf & Dominik Wolf. 2018. Small Molecules in Hematology. Small Molecules in Hematology
87
108
.
Qian Jiang, Haibo Wang, Lu Yu & Robert Peter Gale. (2017) Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 143:12, pages 2619-2630.
Crossref
Crossref
Qian Jiang, Hai-Bo Wang, Lu Yu & Robert Peter Gale. (2017) Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. Journal of Cancer Research and Clinical Oncology 143:6, pages 1013-1022.
Crossref
Crossref
Fabio Efficace & Laura Cannella. (2016) The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology 2016:1, pages 170-179.
Crossref
Crossref